Reata Appoints Manmeet S. Soni as Chief Financial Officer; Jason D. Wilson to Assume New Role as EVP, Operations
August 28 2019 - 4:01PM
Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage
biopharmaceutical company, today announced the appointment of
Manmeet S. Soni as Chief Financial Officer (CFO) and Executive Vice
President, effective August 28, 2019. Mr. Soni will report to
Reata’s Chief Executive Officer and President, Warren Huff, and
will provide strategic leadership in the overall financial
management of Reata. His responsibilities will include
corporate finance and accounting, information technology, corporate
strategy, corporate communications, and investor relations. Jason
D. Wilson, who has been with Reata since 2006 and served as CFO,
will assume a new role as Executive Vice President of
Operations. Mr. Wilson will continue to report to the Chief
Executive Officer and will oversee Reata’s operations, including
program and clinical operations, manufacturing, bioinformatics,
quality, global alliances, and human resources.
“We are thrilled to welcome Manmeet, a proven
leader in the biotechnology industry who has successfully
transitioned several biopharmaceutical companies from
development-stage to commercial entities,” said Mr. Huff.
“Manmeet’s depth of experience will add another seasoned executive
to our management team and will be invaluable to Reata at this
pivotal moment in the company’s history.”
Mr. Soni brings over 20 years of finance
industry experience with seven years in financial leadership roles
within the biopharmaceutical industry. Most recently, Mr.
Soni served as the CFO of Alnylam Pharmaceuticals where he led the
buildout of Alnylam’s global financial and commercial
infrastructure and helped secure more than $2 billion in new
capital and collaboration agreements. Prior to Alnylam, Mr.
Soni served as the CFO at ARIAD Pharmaceuticals where he played a
vital role in its acquisition by the Takeda Pharmaceutical Company
for $5.2 billion. Before joining ARIAD, Mr. Soni served as CFO at
Pharmacyclics where he played a strategic and primary role in its
acquisition by AbbVie for $21 billion. Mr. Soni is currently a
board member at Pulse Biosciences and Arena
Pharmaceuticals.
“I am elated to be joining Reata at this key
stage in the company’s evolution. Having been involved in multiple
new pharmaceutical product launches in the past, I am gratified to
play a role in bringing Reata’s novel therapies to patients with
severe and underserved orphan diseases,” said Mr. Soni.
About Reata Pharmaceuticals,
Inc.
Reata is a clinical-stage biopharmaceutical
company that develops novel therapeutics for patients with serious
or life-threatening diseases by targeting molecular pathways
involved in the regulation of cellular metabolism and
inflammation. Reata’s two most advanced clinical candidates,
bardoxolone methyl (bardoxolone) and omaveloxolone, target the
important transcription factor Nrf2 that promotes restoration of
mitochondrial function, reduction of oxidative stress, and
inhibition of pro-inflammatory signaling. Bardoxolone
and omaveloxolone are investigational drugs, and their safety and
efficacy have not been established by any agency.
Forward-Looking Statements
This press release includes certain disclosures
that contain “forward-looking statements,” including, without
limitation, statements regarding the success, cost and timing of
our product development activities and clinical trials, our plans
to research, develop and commercialize our product candidates, and
our ability to obtain and retain regulatory approval of our product
candidates. You can identify forward-looking statements
because they contain words such as “believes,” “will,” “may,”
“aims,” “plans,” “model,” and “expects.” Forward-looking
statements are based on Reata’s current expectations and
assumptions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks, and
changes in circumstances that may differ materially from those
contemplated by the forward-looking statements, which are neither
statements of historical fact nor guarantees or assurances of
future performance. Important factors that could cause actual
results to differ materially from those in the forward-looking
statements include, but are not limited to, (i) the timing, costs,
conduct, and outcome of our clinical trials and future preclinical
studies and clinical trials, including the timing of the initiation
and availability of data from such trials; (ii) the timing and
likelihood of regulatory filings and approvals for our product
candidates; (iii) the potential market size and the size of the
patient populations for our product candidates, if approved for
commercial use, and the market opportunities for our product
candidates; and (iv) other factors set forth in Reata’s filings
with the U.S. Securities and Exchange Commission, including its
Annual Report on Form 10-K, under the caption “Risk Factors.”
The forward-looking statements speak only as of the date made and,
other than as required by law, we undertake no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events, or otherwise.
Contact:Reata Pharmaceuticals, Inc.(972)
865-2219http://reatapharma.com/
Investor Relations:Vinny JindalVice President,
Strategy(469)
374-8721ir@reatapharma.comhttp://reatapharma.com/contact-us/
Media:Matt Middleman, M.D.LifeSci Public
Relations(646)
627-8384matt.middleman@lifescipublicrelations.com
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Sep 2023 to Sep 2024